$4.66
0.00% (Daily)
Market Cap
$1.05B
Revenue
$70.74M
Rank by MCap
#1883
Sector
Healthcare
Industry
Biotechnology
Headquarters
Tübingen
Employees
825
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs huma...
Loading chart…